Naumann, P.* ; Eberlein, J.* ; Farnia, B.* ; Liermann, J.* ; Hackert, T.* ; Debus, J.* ; Combs, S.E.
     
 
    
        
Cachectic body composition and inflammatory markers portend a poor prognosis in patients with locally advanced pancreatic cancer treated with chemoradiation.
    
    
        
    
    
        
        Cancers 11:1655 (2019)
    
    
    
		
		
			
				Background: Patients with pancreatic cancer often develop cancer cachexia, a complex multifactorial syndrome with weight loss, muscle wasting and adipose tissue depletion with systemic inflammation causing physical impairment. In patients with locally advanced pancreatic cancer (LAPC) neoadjuvant treatment is routinely performed to allow a subsequent resection. Herein, we assess body composition and laboratory markers for cancer cachexia both before and after neoadjuvant chemoradiation (CRT). Methods: Subcutaneous fat (SCF), visceral fat (VF), skeletal muscle (SM), weight and laboratory parameters were determined longitudinally in 141 LAPC patients treated with neoadjuvant CRT. Changes during CRT were statistically analyzed and correlated with outcome and Kaplan-Meier curves were plotted. Different prognostic factors linked to cachexia were assessed by uni- and multivariable cox proportional hazards models. Results: There was a significant decrease in weight as well as SCF, VF and SM during CRT. The laboratory parameter C-reactive protein (CRP) increased significantly, whereas there was a significant decrease in leukocyte count, hemoglobin, albumin and cholinesterase as well as in the tumor marker CA 19.9. Cachectic weight loss, sarcopenia, reductions in body compartments SCF, VF and SM, and changes in laboratory markers as well as resection affected survival in univariable analysis. In multivariable analysis, weight loss >5% (HR 2.8), reduction in SM >5% (HR 5.5), an increase in CRP (HR 2.2) or CA 19.9 (HR 1.9), and resection (HR 0.4) remained independently associated with survival, whereas classical cachexia and sarcopenia did not. Interestingly, the subgroup of patients with cachectic weight loss >5% or SM reduction >5% during CRT did not benefit from resection (median survival 12 vs. 27 months). Conclusions: Persistent weight loss and muscle depletion during CRT as well as systemic inflammation after CRT impacted survival more than cachexia or sarcopenia according classical definitions.
			
			
				
			
		 
		
			
				
					
					Impact Factor
					Scopus SNIP
					Web of Science
Times Cited
					Scopus
Cited By
					
					Altmetric
					
				 
				
			 
		 
		
     
    
        Publikationstyp
        Artikel: Journalartikel
    
 
    
        Dokumenttyp
        Wissenschaftlicher Artikel
    
 
    
        Typ der Hochschulschrift
        
    
 
    
        Herausgeber
        
    
    
        Schlagwörter
        Locally Advanced Pancreatic Cancer ; Chemoradiation ; Cachexia ; Weight Loss ; Muscle Wasting ; Adipose Tissue ; Body Composition ; Skeletal Muscle Index ; Sarcopenia; Ductal Adenocarcinoma; Neoadjuvant Chemoradiation; Anthropometric Changes; Skeletal-muscle; Cachexia; Survival; Therapy; Impact; Classification; Sarcopenia
    
 
    
        Keywords plus
        
    
 
    
    
        Sprache
        englisch
    
 
    
        Veröffentlichungsjahr
        2019
    
 
    
        Prepublished im Jahr 
        
    
 
    
        HGF-Berichtsjahr
        2019
    
 
    
    
        ISSN (print) / ISBN
        2072-6694
    
 
    
        e-ISSN
        
    
 
    
        ISBN
        
    
 
    
        Bandtitel
        
    
 
    
        Konferenztitel
        
    
 
	
        Konferzenzdatum
        
    
     
	
        Konferenzort
        
    
 
	
        Konferenzband
        
    
 
     
		
    
        Quellenangaben
        
	    Band: 11,  
	    Heft: 11,  
	    Seiten: ,  
	    Artikelnummer: 1655 
	    Supplement: ,  
	
    
 
  
        
            Reihe
            
        
 
        
            Verlag
            MDPI
        
 
        
            Verlagsort
            St Alban-anlage 66, Ch-4052 Basel, Switzerland
        
 
	
        
            Tag d. mündl. Prüfung
            0000-00-00
        
 
        
            Betreuer
            
        
 
        
            Gutachter
            
        
 
        
            Prüfer
            
        
 
        
            Topic
            
        
 
	
        
            Hochschule
            
        
 
        
            Hochschulort
            
        
 
        
            Fakultät
            
        
 
    
        
            Veröffentlichungsdatum
            0000-00-00
        
 
         
        
            Anmeldedatum
            0000-00-00
        
 
        
            Anmelder/Inhaber
            
        
 
        
            weitere Inhaber
            
        
 
        
            Anmeldeland
            
        
 
        
            Priorität
            
        
 
    
        Begutachtungsstatus
        Peer reviewed
    
 
     
    
        POF Topic(s)
        30203 - Molecular Targets and Therapies
    
 
    
        Forschungsfeld(er)
        Radiation Sciences
    
 
    
        PSP-Element(e)
        G-501300-001
    
 
    
        Förderungen
        
    
 
    
        Copyright
        
    
 	
    
    
    
    
    
        Erfassungsdatum
        2019-11-25